MARCO promotes cholangiocarcinogenesis by inducing immunosuppression and its targeting reduces tumour growth
Ontology highlight
ABSTRACT:
INSTRUMENT(S): timsTOF Pro
ORGANISM(S): Mus Musculus (ncbitaxon:10090)
SUBMITTER: 
Jesus Maria Banales Maria Jesis Perugorria
PROVIDER: MSV000100316 | MassIVE | Tue Dec 23 05:38:00 GMT 2025
SECONDARY ACCESSION(S): PXD072349
REPOSITORIES: MassIVE
Similar Datasets
Project description:The paper describes a model of interaction of Th cells and macrophage in melanoma.
Created by COPASI 4.25 (Build 207)
This model is described in the article:
Modelling and investigation of the CD4 T cells – Macrophages paradox in melanoma immunotherapies
Raluca Eftimie, Haneen Hamam
Journal of Theoretical Biology 420 (2017) 82–104
Abstract:
It is generally accepted that tumour cells can be eliminated by M1 anti-tumour macrophages and CD8+ T cells. However, experimental results over the past 10–15 years have shown that B16 mouse melanoma cells can be eliminated by the CD4+ T cells alone (either Th1 or Th2 sub-types), in the absence of CD8+ T cells. In some studies, elimination of B16 melanoma was associated with a Th1 immune response (i.e., elimination occurred in the presence of cytokines produced by Th1 cells), while in other studies melanoma elimination was associated with a Th2 immune response (i.e., elimination occurred in the presence of cytokines produced by Th2 cells). Moreover, macrophages have been shown to be present inside the tumours, during both Th1 and Th2 immune responses. To investigate the possible biological mechanisms behind these apparently contradictory results, we develop a class of mathematical models for the dynamics of Th1 and Th2 cells, and M1 and M2 macrophages in the presence/absence of tumour cells. Using this mathematical model, we show that depending on the re- polarisation rates between M1 and M2 macrophages, we obtain tumour elimination in the presence of a type-I immune response (i.e., more Th1 and M1 cells, compared to the Th2 and M2 cells), or in the presence of a type- II immune response (i.e., more Th2 and M2 cells). Moreover, tumour elimination is also possible in the presence of a mixed type-I/type-II immune response. Tumour growth always occurs in the presence of a type-II immune response, as observed experimentally. Finally, tumour dormancy is the result of a delicate balance between the pro-tumour effects of M2 cells and the anti-tumour effects of M1 and Th1 cells.
To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models .
To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide.
Please refer to CC0 Public Domain Dedication for more information.
2024-09-02 | BIOMD0000000769 | BioModels
Project description:The paper describes a model of interaction of Th cells and macrophage in melanoma.
Created by COPASI 4.25 (Build 207)
This model is described in the article:
Modelling and investigation of the CD4 T cells – Macrophages paradox in melanoma immunotherapies
Raluca Eftimie, Haneen Hamam
Journal of Theoretical Biology 420 (2017) 82–104
Abstract:
It is generally accepted that tumour cells can be eliminated by M1 anti-tumour macrophages and CD8+ T cells. However, experimental results over the past 10–15 years have shown that B16 mouse melanoma cells can be eliminated by the CD4+ T cells alone (either Th1 or Th2 sub-types), in the absence of CD8+ T cells. In some studies, elimination of B16 melanoma was associated with a Th1 immune response (i.e., elimination occurred in the presence of cytokines produced by Th1 cells), while in other studies melanoma elimination was associated with a Th2 immune response (i.e., elimination occurred in the presence of cytokines produced by Th2 cells). Moreover, macrophages have been shown to be present inside the tumours, during both Th1 and Th2 immune responses. To investigate the possible biological mechanisms behind these apparently contradictory results, we develop a class of mathematical models for the dynamics of Th1 and Th2 cells, and M1 and M2 macrophages in the presence/absence of tumour cells. Using this mathematical model, we show that depending on the re- polarisation rates between M1 and M2 macrophages, we obtain tumour elimination in the presence of a type-I immune response (i.e., more Th1 and M1 cells, compared to the Th2 and M2 cells), or in the presence of a type- II immune response (i.e., more Th2 and M2 cells). Moreover, tumour elimination is also possible in the presence of a mixed type-I/type-II immune response. Tumour growth always occurs in the presence of a type-II immune response, as observed experimentally. Finally, tumour dormancy is the result of a delicate balance between the pro-tumour effects of M2 cells and the anti-tumour effects of M1 and Th1 cells.
To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models .
To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide.
Please refer to CC0 Public Domain Dedication for more information.
2024-09-02 | BIOMD0000000770 | BioModels
Project description:The paper describes a model of re-polarisation of M2 and M1 macrophages and its role on cancer outcomes.
Created by COPASI 4.25 (Build 207)
This model is described in the article:
The re-polarisation of M2 and M1 macrophages and its role on cancer outcomes
den Breems, Nicoline Y.; Eftimie, Raluca
Journal of Theoretical Biology, 390, 23-39
Abstract:
The anti-tumour and pro-tumour roles of Th1/Th2 immune cells and M1/M2 macrophages have been documented by numerous experimental studies. How- ever, it is still unknown how these immune cells interact with each other to control tumour dynamics. Here, we use a mathematical model for the inter- actions between mouse melanoma cells, Th2/Th1 cells and M2/M1 macro- phages, to investigate the unknown role of the re-polarisation between M1 and M2 macrophages on tumour growth. The results show that tumour growth is associated with a type-II immune response described by large num- bers of Th2 and M2 cells. Moreover, we show that: (i) the ratio k of the transition rates k12 (for the re-polarisation M1→M2) and k21 (for the re- polarisation M2→M1) is important in reducing tumour population, and (ii) the particular values of these transition rates control the delay in tumour growth and the final tumour size. We also perform a sensitivity analysis to investigate the effect of various model parameters on changes in the tumour cell population, and confirm that the ratio k alone and the ratio of M2 and M1 macrophage populations at earlier times (e.g., day 7), cannot always predict the final tumour size.
To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models .
To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide.
Please refer to CC0 Public Domain Dedication for more information.
2024-09-02 | BIOMD0000000759 | BioModels
Project description:Colorectal cancer (CRC) is the third most diagnosed type of cancer and the second leading cause of cancer death worldwide. Despite the increasing knowledge of CRC molecular biology and the development of new targeted therapies, its high heterogeneity hampers the efficacy of current treatments. Thus, there is a pressing need to identify new effective therapeutic targets and improve immune therapies for these patients. In this regard, S-nitrosoglutathione reductase (GSNOR) is a denitrosylase enzyme that has been suggested to play a tumour suppressor role, although the mechanisms responsible are still largely unclear. Therefore, the main objective of this project was to understand the role of GSNOR in CRC tumorigenesis and its therapeutic implications. Firstly, we classified CRC tumours as GSNOR-high or low according to their GSNOR expression as assessed by immunohistochemistry (IHC). Accordingly, we found that GSNOR deficiency was associated with worse prognosis factors such as a larger tumour size at diagnosis, higher TNM stage, higher grade of tumour budding (TB), the CMS4 subtype, lower expression of the intestinal differentiation markers CDX2 and AE1/AE3 cytokeratin and a worse progression free survival (PFS) and overall survival (OS). We next investigated the differences in gene expression between CRC GSNOR-high and low tumours, uncovering significant alterations in metabolism and immune system pathways. Hence, GSNOR-deficient tumours were characterized by immune suppressive features and a dysregulation of their metabolism, favouring other metabolic pathways than OXPHOS.
2024-04-13 | GSE263844 | GEO
Project description:Gamma-delta T cells are important for host defence at the respiratory mucosa, acting directly or through interactions with other cells. However, how Gamma-Delta T cells influence other immune cells in the lung remains unclear. Using a genetically engineered mouse model of lung cancer, we show that tumours drive expansion of both CD27+ and CD27— Gamma-Delta T cells. Advanced microscopy techniques indicated that CD27— Gamma-Delta T cells are enriched in tumours, while CD27+ Gamma-Delta T cells are more prone to interact with macrophages in tumour-associated adventitial cuffs. SiglecFlow pro-fibrotic airway macrophages were more prevalent in lung tumour-bearing mice than tumour-free mice. This pro-fibrotic subset was reduced in lungs when the cancer model was crossed to Tcrd knockout mice or treated with V Gamma1-depleting antibodies, but not in TcrgV4/6 knockout mice. Thus, our findings implicate V Gamma1 Gamma-Delta T cells in driving tumour-associated airway macrophage functional imprinting. Determining the translatability to human health may offer new avenues for refining patient management and immunotherapeutic strategies.
2026-02-04 | GSE307499 | GEO
Project description:Gamma-delta T cells are important for host defence at the respiratory mucosa, acting directly or through interactions with other cells. However, how Gamma-Delta T cells influence other immune cells in the lung remains unclear. Using a genetically engineered mouse model of lung cancer, we show that tumours drive expansion of both CD27+ and CD27— Gamma-Delta T cells. Advanced microscopy techniques indicated that CD27— Gamma-Delta T cells are enriched in tumours, while CD27+ Gamma-Delta T cells are more prone to interact with macrophages in tumour-associated adventitial cuffs. SiglecFlow pro-fibrotic airway macrophages were more prevalent in lung tumour-bearing mice than tumour-free mice. This pro-fibrotic subset was reduced in lungs when the cancer model was crossed to Tcrd knockout mice or treated with V Gamma1-depleting antibodies, but not in TcrgV4/6 knockout mice. Thus, our findings implicate V Gamma1 Gamma-Delta T cells in driving tumour-associated airway macrophage functional imprinting. Determining the translatability to human health may offer new avenues for refining patient management and immunotherapeutic strategies.
2026-02-04 | GSE307497 | GEO
Project description:In addition to the tumour cells, breast tumours contain other cell types such as fibroblasts, adipocytes, inflammatory and immune cells. Together with the extracellular matrix, these non-tumour cells compose the tumour microenvironment (TME). Complex interactions occur between tumour cells and the TME that can inhibit or stimulate tumour cell growth, metastasis and/or chemoresistance. While treatment of tumours with chemotherapeutic agents such as Abraxane, leads to apoptosis of tumour cells, it can also have consequences for the cellular makeup and transcriptional profile of the TME and these, like the increased infiltration of macrophages, may have detrimental effects. Transcriptome profiling of whole tumours from mice injected with tumour cell lines and treated with combinations of chemotherapeutic drugs has provided novel insights into pathways affected by different agents and diagnostic signatures. However, differences in the cellular composition of tumours from treated mice can have confounding effects and increase variation in whole tumour transcriptomes. To be able to examine the effects of co-treatment of Abraxane with another drug, we performed RNA-seq on tumours from mice injected with the human breast cancer cell line MDA-MB-231. We then separated reads mapped to the human and mouse genomes in silico, creating tumour and TME transcriptomes for control, Abraxane, drug and combination treated mice. Separation of the tumour and TME profiles revealed that while in the tumour cells, co-addition of the drug potentiated Abraxane’s inhibitory effect on cell cycle genes and promotional effect on antigen presentation genes, in the TME it inhibited genes involved in the inflammation and migration responses and promoted genes involved in lipid and xenobiotic metabolism.
2020-10-01 | GSE121119 | GEO
Project description:Owen1998 - tumour growth model
Deterministic model for the early,
avascular growth of a tumour, concentrating on the inhibitory
effect of macrophages.
This model is described in the article:
Modelling the macrophage
invasion of tumours: effects on growth and composition.
Owen MR, Sherratt JA.
IMA J Math Appl Med Biol 1998 Jun;
15(2): 165-185
Abstract:
Even in the early stages of their development, tumours are
not simply a homogeneous grouping of mutant cells; rather, they
develop in tandem with normal tissue cells, and also recruit
other cell types including lymphatic cells and the endothelial
cells required for the development of a blood supply. It has
been repeatedly seen that macrophages form a significant
proportion of the tumour mass, and that they can have a variety
of effects upon the tumour, leading to a delicate balance
between growth promotion and inhibition. This paper develops a
model for the early, avascular growth of a tumour,
concentrating on the inhibitory effect of macrophages due to
their cytolytic activity. It is shown that such an immune
response is not sufficient to prevent growth, due to it being a
second-order process with respect to the density of the tumour
cells present. However, the presence of macrophages does have
important effects on the tumour composition, and the authors
perform a detailed bifurcation analysis of their model to
clarify this. An extended model is also considered which
incorporates addition of exogenous chemical regulators. In this
case, the model admits the possibility of tumour regression,
and the therapeutic implications of this are discussed.
This model is hosted on
BioModels Database
and identified by:
BIOMD0000000670.
To cite BioModels Database, please use:
Chelliah V et al. BioModels: ten-year
anniversary. Nucl. Acids Res. 2015, 43(Database
issue):D542-8.
To the extent possible under law, all copyright and related or
neighbouring rights to this encoded model have been dedicated to
the public domain worldwide. Please refer to
CC0
Public Domain Dedication for more information.
2024-09-02 | BIOMD0000000670 | BioModels
Project description:Owen1998 - tumour treatment model
This model is described in the article:
Modelling the macrophage
invasion of tumours: effects on growth and composition.
Owen MR, Sherratt JA.
IMA J Math Appl Med Biol 1998 Jun;
15(2): 165-185
Abstract:
Even in the early stages of their development, tumours are
not simply a homogeneous grouping of mutant cells; rather, they
develop in tandem with normal tissue cells, and also recruit
other cell types including lymphatic cells and the endothelial
cells required for the development of a blood supply. It has
been repeatedly seen that macrophages form a significant
proportion of the tumour mass, and that they can have a variety
of effects upon the tumour, leading to a delicate balance
between growth promotion and inhibition. This paper develops a
model for the early, avascular growth of a tumour,
concentrating on the inhibitory effect of macrophages due to
their cytolytic activity. It is shown that such an immune
response is not sufficient to prevent growth, due to it being a
second-order process with respect to the density of the tumour
cells present. However, the presence of macrophages does have
important effects on the tumour composition, and the authors
perform a detailed bifurcation analysis of their model to
clarify this. An extended model is also considered which
incorporates addition of exogenous chemical regulators. In this
case, the model admits the possibility of tumour regression,
and the therapeutic implications of this are discussed.
This model is hosted on
BioModels Database
and identified by:
MODEL1708250002.
To cite BioModels Database, please use:
BioModels Database:
An enhanced, curated and annotated resource for published
quantitative kinetic models.
To the extent possible under law, all copyright and related or
neighbouring rights to this encoded model have been dedicated to
the public domain worldwide. Please refer to
CC0
Public Domain Dedication for more information.
2024-09-02 | BIOMD0000000650 | BioModels
Project description:Increasing evidence indicates that activation of oncogenic pathways contributes to an unfavourable tumour immune microenvironment (TIME), ultimately resulting in resistance to immunotherapy. Here, we aim to identify a critical oncogenic pathway involved in an antigen-expressing c-MYC-lucOSOE/Tp53KO HCC mouse model that simulates immune response against tumour-associated antigens in human HCC. To investigate the intrinsic oncogenic pathway enriched in tumours exhibiting immune evasion, tumour tissues were harvested from c-MYC-lucOE/Tp53KO mice and immune-escaped c-MYC-lucOSOE/Tp53KO mice for DIA proteomics.
2025-09-18 | PXD058362 | Pride